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Abstract 
The chemotherapeutic Doxorubicin (DOX) has significantly increased survival rates of 
pediatric and adult cancer patients. However, 10 % of pediatric cancer survivors will 10-20 
years later develop severe Dilated Cardiomyopathy (DCM) and the exact molecular 
mechanisms of disease progression after this long latency time remain puzzling. We here revisit 
the hypothesis that elevated apoptosis signaling or its increased likelihood after DOX exposure 
can lead to an impairment of cardiac function and cause a cardiac dilation. Based on recent 
literature evidences, we first argue why even little detectable apoptosis may be sufficient to 
cause a dilated phenotype. We then review findings suggesting that mature cardiomyocytes are 
protected against DOX-induced apoptosis downstream, but not upstream to Mitochondrial 
Outer Membrane Permeabilisation (MOMP). This lack of prevention of MOMP-induction then 
is proposed to alter the metabolic phenotype, induce hypertrophic remodeling and lead to 
functional cardiac impairment even in absence of cardiomyocyte apoptosis. We further discuss 
findings that DOX exposure can lead to increased sensitivity to further cardiomyocyte 
apoptosis, which may cause a gradual loss in cardiomyocytes over time and a compensatory 
hypertrophic remodeling after treatment, potentially explaining the long lag time in disease 
onset. We finally note similarities between DOX-exposed cardiomyocytes and apoptosis-
primed cancer cells and propose computational systems biology as tool to predict patient 
individual DOX doses. In conclusion, combining recent findings in rodent hearts and 
cardiomyocytes exposed to DOX with insights from apoptosis signal transduction allowed us 
to obtain a molecularly deeper insight in this delayed and still enigmatic pathology of DCM. 
  
Key messages 
 
1. Differentiated cardiomyocyte are protected to post but not pre-MOMP apoptosis 
2. MOMP-induction can lead to cardiac hypertrophy and metabolic remodeling after DOX 
3. DOX-exposed cardiomyocytes may be more sensitive to apoptosis over life time 
4. DOX-exposed cardiomyocytes show similarities to apoptosis-primed cancer cells  
 
  
Introduction 
Doxorubicin (DOX) is one of the most widely and successfully applied chemotherapeutic drugs 
[1-3] and has increased the 5-year survival rates for pediatric cancer patients from 58% to 80% 
within the last 20 years [4]. However, DOX clinical utility and dosage regimens are often 
limited by severe side effects which can be either acute, sub-acute or late and chronic [5]. While 
acute and sub-acute toxicity are rare (1–4%) and can be managed by adaptation of dosage 
regimens during, or cessation of, treatment, chronic side effects occur often several years after 
treatment [6].  
The most severe chronic side effect of DOX is chronic dilated cardiomyopathy (DCM). Chronic 
DCM leads to cardiac dysfunction and eventually congestive heart failure, resulting in the need 
for heart transplant or even causing death [7]. Chronic DCM occurs in about 10-20% of cancer 
survivors often 10-15 years following treatment [3, 8, 9]. As the likelihood of DCM cannot be 
assessed a priori for an individual patient, the usual dosage of DOX is usually restricted to 60–
75 mg/m² every 3 weeks, hence limiting its efficacy [10].  
The late onset of DCM symptoms after cessation of treatment suggests the presence of a slow 
maladaptive remodeling after initial DOX exposure. Therefore, to understand and mitigate 
DOX induced chronic DCM, several excellent reviews have focused on the effect of DOX-
deregulated oxidative metabolism [11, 12], DOX-induced autophagy [13], or on the broader 
clinical scope of DOX-induced DCM [14]. We here focus on the role of apoptosis to discuss 
potential molecular underpinnings of a chronic DCM phenotype, paying specific attention on 
apoptosis alteration after cardiomyocyte differentiation and DOX exposure.  
Evidence for cardiomyocyte apoptosis in DOX-induced DCM 
Apoptosis may contribute to DOX-induced DCM and heart failure [12, 15-17] either by acute 
apoptotic damage of cardiomyocytes or by mechanisms that increase their future apoptosis 
likelihood. However, the relevance of apoptosis in DOX-induced dilated cardiomyopathy is 
often questioned as the amount of apoptosis in biopsies from patients or from heart transplants 
following DCM is low compared to necrotic cell death [18]. A suggested reason for the low 
amount of apoptosis detected in DCM is that apoptosis gradually evolves over time, initiating 
a slow mechanism of cardiomyocyte hypertrophy over years to replace cardiomyocyte loss [19]. 
In addition to this, apoptosis is often overshadowed by the presence of secondary necrosis. 
Secondary necrosis follows the original apoptotic cell death when scavengers of apoptotic 
debris such as phagocytes operate insufficiently [20] or when ATP levels are too low to 
guarantee robust apoptosis execution [21], both of which are conditions typical in the impaired 
and failing heart [22].  
Indeed, despite the low detectable amount, several studies suggest a functional role of apoptosis 
in DCM. In one study, terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end 
labeling (TUNEL) staining of heart tissue from 21 transplant patients with DCM revealed 
0.119% TUNEL positive cardiomyocytes, indicative of apoptosis. While low, this amount was 
higher than in patients with ischemic heart disease (0.075%) and in control patients (<0.002%), 
and the amount of cardiomyocytes apoptosis positively correlated with disease progression [23]. 
Moreover, in a transgenic mouse model with constitutively active caspase-8 only a small 
detectable elevation of apoptosis only 23 myocytes per 105 cells sufficed to induce a dilated 
cardiomyopathy phenotype [24]. Importantly, this amount is four- to tenfold lower than that 
measured in three independent studies of failing human hearts. Further, mechanistic support for 
a role of cardiomyocyte apoptosis in the development of a dilated phenotype following DOX 
exposure comes for Zhang and colleagues [25]. There, the authors linked the cardiac specific 
isoform of the canonical target of DOX-induced apoptosis, Topisomerase 2 (TOP-2) to a 
DCM phenotype. The authors used a tetracycline-inducible mouse model of TOP-2-deletion 
specific to the heart. Apoptosis was found to be elevated in TOP-2 wild type mice after DOX-
treatment, but not in such where TOP-2 was conditionally deleted. Likewise, DOX treatment 
of TOP-2 wild type mice showed increased left-ventricular end-systolic volume (LVESV), 
increased diastolic volume (LVEDV), and reduced cardiac ejection fraction (EF). Importantly, 
these detrimental effects were ablated after DOX exposure in mice with TOP-2-deletion. 
 
Pathways of cardiomyocyte apoptosis relevant to DOX -induced DCM 
We here first describe DOX-induced caspase-dependent apoptosis as found in cancer cells and 
subsequently discuss evidence of these molecular mechanism that have so far being confirmed 
in cardiomyocytes ([26], Figure 1). We further note that other proteases [27, 28], metabolic 
dysfunction or autophagocytic processes [13] may also play a role in regulating cardiomyocyte 
demise, specifically when canonical caspase activation is blocked or initial injury is too severe 
[15]. 
During cancer treatment, DOX firstly intercalates with cellular DNA leading to trapping of 
topoisomerase II (TOP2), an enzyme that regulates the unfolding of the DNA during replication. 
Inhibition of TOP2 induces genotoxic stress and the activation of p53 [25, 29]. Transcriptional 
activity of p53 biases the levels of pro- and anti-apoptotic proteins of the BCL2 family towards 
the prior by expressing the BCL2 family proteins PUMA and NOXA (Figure 1A), leading to 
the process of Mitochondrial Outer Membrane Permeabilisation (MOMP; Figure 1B). MOMP 
leads to the release of further apoptotic proteins, which initiates the so-called downstream 
apoptosis program, and culminates in caspase activation and cell death (Figure 1C). Besides 
this genotoxic stress induced, intrinsic pathway of apoptosis, an extrinsic path may also be 
induced by binding of cell death ligands such as FAS-L to their receptor (Figure 1D). In this 
step, caspase-3 is activated either by a positive feedback loop with upstream caspase-8 (so-
called type I cells) or after MOMP which is mediated by of the BCL-2 protein BID (type II 
cells). We further note that MOMP induces an energetic crisis caused by the loss of cytochrome-
c, which may lead to necrosis or metabolic impairment when caspase-dependent apoptosis is 
blocked [21, 30, 31]. 
 
The above discussed study of Zhang [32] suggested that cardiomyocyte apoptosis after DOX 
treatment parallels the above mentioned p53-dependent genotoxic stress mechanism from 
cancer cells by targeting the cardiac specific TOP2 isoform. Indeed, p53-dependency was 
further suggested by investigating DOX-induced DCM in a mouse model with conditional 
knock out of the p53-inhibitor MDM4 under presence of p53-null and p53-competent alleles 
[33]. A potential role of the p53 target PUMA, commonly known to be upregulated after 
genotoxic stress in cancer cells [34], has also been suggested to be relevant for cardiomyocyte 
apoptosis in response to DOX as observed for H9C2 cardiomyoblasts [35]. A similar PUMA-
dependency of cardiomyocyte apoptosis has been found in ischemia-reperfusion model of 
cultured cardiomyocyte [36]. This pathway would also involve BCL2-protein interaction [37, 
38], BAX/BAK-induced MOMP [39] and activation of initiator and activator caspases [24, 39, 
40] similar to the above presented canonical intrinsic apoptosis in cancer cells. Likewise, 
invocation of the extrinsic apoptosis program by DOX via FAS-L or TRAIL ligands has also 
been detected in cardiomyocytes similar to cancer cells [41, 42], potentially attaining robust 
caspase-3 activation by invoking MOMP (type II cells, Fig 1).  
 
Are differentiated cardiomyocytes less likely to succumb to DOX-induced 
apoptosis? 
Due to the above motivated similarity in apoptosis pathways between cancer cells and 
cardiomyocytes, any strategy that aims to protect cardiomyocytes while killing cancer cells 
would aim to exploit differences in apoptosis likelihood rather than invoking distinct apoptosis 
pathways [43-45]. To this end, the Deshmukh lab has shown that differentiated rat 
cardiomyocytes, similar to primary neurons, have down-regulated levels of the pro-apoptotic 
APAF-1 and increased expression of the anti-apoptotic XIAP compared to less differentiated 
cells. In agreement with these changes they indeed found a remarkable protection to caspase-3 
activation and post-MOMP apoptosis when they added cytochrome c to their cell cultures. 
Interestingly, this protection was ablated by the XIAP-antagonist SMAC highlighting the 
balance of pro- and anti-apoptotic proteins in the post-MOMP pathway as decisive for this 
cardiomyocyte protection [46, 47]. From their biochemical study, a positive correlation between 
differentiation status and decreased apoptosis likelihood in response to DOX is hence expected. 
Evidence for this hypothesis comes from Konorev et al who exposed three cell types with 
decreasing levels of maturity and differentiation, i.e. adult rat cardiomyocytes (ARCM), 
neonatal rat cardiomyocytes (NRCM), and rat embryonic H9c2 cardiomyoblasts to DOX [40]. 
To assess apoptosis, they used dedicated fluorogenic substrates for caspase-3 and caspase-9 
activity. Their results demonstrated that ARCM had markedly lower caspase-3 and -9 activity 
than both less differentiated cell types. Likewise, mature NRCMs were more robust to apoptosis 
than H9C2 cardiomyoblast. Adding cytochrome c to permeabilised cells confirmed that this 
protection is mediated by apoptosis downstream to MOMP. In contrast, MOMP induction as 
evidenced by cytochrome c release revealed a trend that H9C2 and NRCM cells are more stable 
to apoptosis than the more differentiated ARCM, suggesting little or the absence of apoptosis 
protection due to differentiation upstream to MOMP. Decreased apoptosis susceptibility with 
cardiomyocyte maturity was also proposed in a further study [48]. Comparing post-natal day 7 
to day 21 myocardia and exposing them the DOX, these authors confirmed that caspase-3 
activity decreased by >20 fold and the amount of TUNEL positive cells was significantly 
reduced, most likely due to a significant reduction of APAF-1 and procaspase-9. However, 
despite the down-regulation of the upstream, pro-apoptotic protein BAX during maturation, 
cytochrome c release as indicator for MOMP in response to DOX exposure again did not 
significantly differ between hearts of different maturity. From the above studies we hence 
conclude that protection against DOX induced apoptosis with increased differentiation status is 
exercised downstream to MOMP, while, in contrast, processes upstream to MOMP seem to be 
less protected or show even more susceptibility to MOMP upon differentiation and maturation.  
 
Does DOX exposure change apoptosis likelihood to later somatic 
cardiomyocyte death? 
Apart from acute cardiomyocyte apoptosis after DOX, a higher cell loss after cessation of 
treatment is possible when apoptosis likelihood increases after initial DOX exposure. Apoptosis 
then may then occur gradually over time in response to somatic stimuli resulting in a 
continuously evolving compensatory cardiomyocyte hypertrophy and extracellular matrix 
adaptation to replace cell loss [19].  
Evidence for increased apoptosis likelihood after DOX exposure comes from studies of FAS-
dependent apoptosis. Specifically, rat-derived embryonic cardiomyocytes, which are normally 
resistant to FAS-L induced apoptosis [41], may get sensitized to FAS-L when pre-exposed to 
DOX [49, 50]. Interestingly, DOX pre-exposure may also induce increased FAS-L released by 
rat-derived embryonic cardiomyocytes [41], suggesting a DOX-sensitization dependent 
autocrine/paracrine mechanism for cardiac apoptosis induction. Indeed, elevated FAS-L 
expression was further found to be a risk factor for idiopathic DCM [51], overload-induced 
DCM [52] and for inducing apoptosis-mediated cardiac dilation and dysfunction after anti-viral 
therapy [53], suggesting a role of FAS-L in developing a hypertrophic phenotype. 
 
Besides changes in the secretion of paracrine factors, an increased apoptosis likelihood usually 
arises by shifting the balance between pro- and anti-apoptotic proteins. In the context of cancer 
cells this mechanism was coined as apoptosis priming, aiming to explain why cancer cells are 
more susceptible to chemotherapy than normal cells. Specifically, proponents of the priming 
hypothesis such as the Letai group suggest that cancer cells increase their apoptosis likelihood 
in response to continuous somatic attack by the immune system [45, 54], making them more 
likely than somatic cells to respond to cytotoxic chemotherapy. Indeed, we observe some 
parallelism between cancer cells primed by somatic apoptosis [45, 55] and cardiomyocyte being 
exposed to (sub-lethal) DOX with respect to metabolic programming and apoptosis 
sensitization (Figure 2). 
Evidences that DOX exposure can lead to apoptosis sensitization similar to cancer cell priming 
comes a study which found a decrease in mRNA expression of the anti-apoptotic BCL-2 and 
increase of pro-apoptotic BAX [56]. Likewise, in the aforementioned study of Zhang an up-
regulation of mRNA transcripts was found for the pro-apoptotic gene APAF-1, BAX and FAS-
L after DOX exposure in mice with wild type TOP-2. Moreover, re-analyzing their Gene 
expression Omnibus data set (GSE36239), we also found a transcriptional up-regulation of 
XAF1, an inhibitor of the anti-apoptotic protein XIAP under the top 200 regulated genes in wild 
type mice after DOX exposure. How this XAF-1 up-regulation together with de-regulation of 
other apoptosis genes may lead to elevated apoptosis likelihood in presence of wild type TOP-
2miceis illustrated by an in house computational model of apoptosis signal transduction as 
given and described in Figure 3. Together, these findings suggest an apoptosis priming by DOX 
on a transcriptional level, making cardiomyocytes more likely to respond to further apoptosis 
stimuli [25]. 
Similar as in the case of cardiomyocyte differentiation, however, the change in apoptosis 
sensitivity after DOX pre-exposure seems to be different between pathways upstream and 
downstream to MOMP. Hence, increased protection against MOMP after DOX exposure, and 
hence a counter-priming, is indicated by elevation of the anti-apoptotic protein BCL2 [23], by 
an increase of BCL2/BAX protein ratio [57] and elevation of the anti-apoptotic gene ARC in 
rat hearts [58, 59]. As most of these studies were performed in whole hearts, further studies will 
reveal to what extent DOX primes or anti-primes cardiomyocytes to further pre- or post-MOMP 
apoptosis or to apoptosis susceptibility to cell death ligands. 
 
Does DOX-induced MOMP render functionally impaired cardiomyocytes 
even in the absence of apoptosis? 
The above studies suggest that cardiomyocytes acquire robustness against caspase-activation 
upon differentiation. In contrast, the likelihood of MOMP induction following apoptosis stimuli 
seems to be unaffected by differentiation, or even higher than in undifferentiated cells [40, 46, 
48]. Moreover, as also outline above, MOMP may be induced by elevated FAS signaling after 
DOX. We therefore argue that protection against downstream apoptosis in differentiated 
cardiomyocytes in the presence of MOMP following acute DOX exposure may not be sufficient 
to guarantee viable, functional cells [60].  
The first argument is that cytochrome-c release following MOMP deprives mitochondria of this 
important electron carrier in the mitochondrial respiration chain. This deprivation induces a 
bioenergetics crisis [57] consisting of lack of ATP production and failure of ionic homeostasis 
[61] and can directly lead to necrotic cell death in some cardiomyocytes and hence further 
cardiac injury. To avoid such necrosis, some cells have developed means to compensate the 
lack of functional mitochondria by a switch towards increased glycolysis, thereby maintaining 
ATP levels and ionic homeostasis after MOMP [62] [30]. Evidence for the presence of such a 
switch also in DOX-exposed cardiomyocytes comes from the observation of a shift from 
mitochondrial to glycolytic metabolism in the hearts of patients with DOX-induced or 
idiopathic DCM [3, 5, 63, 64]. The presence of such a glycolytic switch is further backed up by 
the fact that glucose transporter type I (GLUT1, the embryonic isoform[65]) was elevated in rat 
hearts after DOX and led to higher glucose import [66] to address the higher glucose demand 
by glycolysis. Together, these findings raise the possibility that DOX-induced MOMP can 
either kill cardiomyocytes by necrosis or invoke glycolytic remodeling. While this remodeling 
may keep cardiomyocytes viable, they may remain less functional as glycolysis may not 
sufficiently address the high energy demand in the heart [5, 63, 64] [22].  
 
Another argument that suppression of downstream apoptosis after MOMP is not sufficient to 
guarantee functional cardiomyocytes is that despite suppression of caspase-3 activation in 
differentiated cardiomyocytes, its activity may not be completely abolished after DOX 
exposure. Indeed, mild, non-lethal caspase-3 activity can lead to structural remodeling such as 
seen in other large cells [67]. As nicely shown by single cell imaging and quantitative systems 
biology studies of apoptosis, such sub-lethal caspase-3 activity can arise when tipping the 
balance for expression of proteins relevant in the post-MOMP pathway from pro-apoptotic to 
anti-apoptotic ones [31, 68, 69]. Indeed, a recent study also demonstrated that apoptosome 
dependent, sub-lethal caspase-activity can also lead, and even is essential, in a model of 
cardiomyocyte hypertrophic remodeling [70]. Specifically using hypertrophy inducing 
agonists, these study authors demonstrated that caspase-9 and caspase-3 were activated in the 
cardiomyocytes at an extent that was too low to induce apoptosis. Cardiomyocyte hypertrophy 
was ablated after either blocking caspase-9 and caspase-3. Likewise, in the rat myocardium the 
hypertrophic phenotype was attenuated after hypertrophy inducing agonist when caspase-3 was 
blocked. Most interestingly, activating caspase-3 with targeted pharmacologic activators (PAC-
1 compounds) was sufficient to induce cardiomyocyte hypertrophy in the absence of other 
hypertrophy-inducing stimuli. These findings are consistent with previous findings of a relation 
between incomplete apoptosis, sub-lethal caspase-3 activity and non-functional cardiomyocytes 
(‘zombie cells‘) that were found in patients with a DCM phenotype [71].  We therefore propose 
that structural remodeling of cardiomyocytes after DOX may partly be a consequence of sub-
lethal caspase activation following acute DOX treatment, as differentiated cardiomyocytes 
show attenuated, but potentially not completely blocked caspase-3 activation after MOMP. 
 The apoptosis hypothesis relevant to other pathways in DOX-induced injury 
Whether or not apoptosis is the dominant regulator of DOX-induced DCM remains 
controversial. Nevertheless, apoptosis has also been implicated in most of the concurring 
models of DOX-induced DCM. To this end, increased production of ROS is considered to be a 
major inducer of cardiac malignancy following DOX [12]. ROS is usually thought to be 
elevated in cardiomyocyte by DOX binding to cardiolipin at the inner mitochondrial membrane, 
impairing mitochondrial respiration [72]. ROS after DOX exposure can also be induced by 
altering endothelial nitric oxidase signaling leading further to reduced production of the cardiac 
vasodilator NO [73]. Both, increased ROS and lack NO can hence directly impair the 
myocardium and heart muscle compliance even in the absence of apoptosis [74].  Besides this 
direct impairment of cardiac function, ROS-induced oxidative stress can also induce 
cardiomyocyte apoptosis [75]. Thereby, oxidative stress has been shown to transcriptionally 
alter BCL-2 family protein expression, leading to MOMP and cytochrome-c release [12, 76]. 
Hence, any DOX-dependent apoptosis sensitization as proposed here may exacerbate ROS-
induced impairment of cardiac viability. Conversely, it is possible that apoptosis sensitization 
after DOX exposure results from oxidative stress-induced transcription of pro-apoptotic 
proteins [77].     
The interplay between protective autophagocytic processes and apoptosis was also suggested 
to be a regulator of DOX-inducted injury [13, 78], potentially allowing the alleviation of 
metabolic stress after MOMP or after other ROS-induced impairment of mitochondria [72]. 
Indeed, upregulation of the major autophagy inducer Beclin-1 has been observed in 
cardiomyocytes in a time and dose dependent manner after DOX exposure [78]. Importantly, 
as Beclin-1 is a substrate of caspase-3, the down-regulation of caspase-3 activity in 
differentiated cardiomyocytes may guarantee execution of autophagy, therefore alleviating 
cellular metabolic injury. Nevertheless, activity of autophagocytation of mitochondria 
(mitophagy), which may become damaged after DOX-induced MOMP, has been also shown to 
be detrimental. To this end, first and recent literature indications point to positive correlation 
between mitophagy and sensitization to DOX-injury, although the causative role of mitophagy 
remains yet open [79, 80].    
Limitations of current studies on the effect of DOX exposure  
Our study is dedicated to the relevance of apoptosis signaling in DOX induced DCM with a 
focus of how cardiomyocyte sensitivity to apoptosis depends on maturation and differentiation 
state and to previous exposure to DOX. We have therefore limited our report to the analysis of 
whole heart tissue and dedicated cardiomyocyte studies. Yet, DOX susceptibility to apoptosis 
in other relevant cells such as in bovine aortic endothelial cells were also reported and apoptosis 
may act in a p53-dependent and independent way [81]. Consistent with our focus on 
cardiomyocytes, we have further limited the discussion of sub lethal caspase-activation to 
structural remodeling and not considered other potential effects such as caspase-induced 
cellular hyper-proliferation, potentially relevant in other cardiac cells [82].  
Conclusion and Outlook 
In this review we discussed DOX-induced DCM from the perspective of how cardiomyocyte 
sensitivity to apoptosis depends on differentiation state and previous exposure to DOX. Still, 
the relation between differentiation, DOX-exposure and apoptosis likelihood requires further 
investigation of a cardiomyocyte level. This may be done by differentiating H9C2 
cardiomyoblast [83], cardiac progenitor cells or inducible pluripotent stem cells and by pre-
exposing the differentiated cells to mild DOX that would not kill the cells, but rather alter their 
composition of cell death proteins.  
We further note that changes of protein expressions relevant to apoptosis can be subtle and that 
regulation of proteins in response to differentiation and DOX pre-exposure have to be studied 
in their interplay. As such example, the studies of Potts [46] and Konorev [40] agreed that post-
MOMP apoptosis is markedly reduced upon cell maturation, but attributed this effect to 
different protein regulation patterns. We therefore propose computational signal transduction 
models to investigate the effect of how combined changes in protein expression levels translate 
to cardiomyocyte vulnerability. Figure 3 illustrates how such models can be exploited to 
quantitatively assess apoptosis likelihood in presence and absence of DOX pre-exposure from 
expression data relevant to apoptosis proteins. Our model illustrates that, while regulation 
patterns of genes and proteins may be more diffuse between subjects and conditions, their 
combined action in a defined pathway can lead to a clearer regulation pattern of apoptosis. 
Indeed, with such quantitative signal transduction models, we were previously able to predict 
patient specific susceptibility to chemotherapy [31, 44, 54, 84, 85]. It is therefore expected that 
these models in combination with biomolecular studies that investigate molecular mediators of 
apoptosis can further help to identify patient more vulnerable to DOX-induced cardiac apoptosis 
and DCM. These computer models may further predict targets for secondary treatments such as 
dexrazoan [86] that reduce cardiomyocyte apoptosis after DOX, while leavings DOX’s action 
in cancer cells intact. 
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Figure 1: Canonical apoptosis pathways following DOX exposure 
The canonical pathway of apoptosis following DOX and other topoisomerase inhibitors is 
depicted. Apoptotic players no yet demonstrated in cardiomyocytes are indicated with a 
question mark. (A-C) The intrinsic pathway of apoptosis following genotoxic stress by TOP II 
inhibition is given. (A) Trapping of TOP II after DOX exposure leads to p53-dependent 
upregulation of the pro-apoptotic BCL-2 protein family member PUMA and NOXA (not yet 
shown in cardiomyocytes). This upregulation changes the balance of pro- and anti-apoptotic 
BCL-2 protein family members towards the prior, and culminates in the activation of BAK and 
BAX to form pores in the mitochondrial outer membrane, leading to MOMP. (B) During 
MOMP, the pro-apoptotic proteins cytochrome-c and SMAC (?) are released. (C) Downstream 
apoptosis after MOMP is mediated by the APAF-1 (?) apoptosome-dependent activation of 
caspase-9 and -3 leading to cell death. Downstream apoptosis is negatively and positively 
regulated by XIAP and SMAC, respectively. The likelihood of downstream apoptosis was 
suggested to be reduced after differentiation [40, 46] and increased after cardiomyocytes have 
been exposed by DOX before (cite: Zhang) (D) Extrinsic apoptosis is mediated by cell death 
ligands such as FAS-L binding to their receptor. This binding leads to a conformational change 
of the cytosolic moiety of the receptor, recruiting the adaptor protein FADD and caspase-8. 
Caspase-8 gets auto-activated by proximity and this process is regulated by long and short 
isoforms of FLIP. In type I cells, robust caspase-3 activation is initiated its activation and due 
to a positive feedback with caspase-8. In type II cells, MOPM is further initiated by caspase-8 
mediated cleavage and activation of the BCL-2 family protein BID. Cardiomyocytes have been 
shown to release FAS-L after DOX [41] while getting also sensitized to DOX and respond to it 
in an auto/paracrine manner [49]. (E) Due to the absence of cytochrome-c in the mitochondrial 
inter membrane space, MOMP can lead to a bioenergetics crisis with loss of mitochondrial 
polarization, reduced ATP production, failure of ionic homeostasis. This mechanism may lead 
to necrosis or a maladaptive metabolic phenotype rendering cardiomyocytes less functional [30, 
62].  
 
Figure 2: DOX-exposure of cardiomyocyte as analogy to apoptosis priming in 
cancer cells 
Analogies between cardiomyocytes exposed to DOX and cancer cells primed to apoptosis in 
the body. This hypothesis is linking toxic pre-exposure to apoptosis sensitization, metabolic 
remodeling and differentiation status. (Left panel) Cardiomyocytes exposed to DOX have a 
tendency to change from oxidative to glycolytic mechanism and to show a functional 
impairment [5, 63], potentially also associated with a switch to fetal gene expression program 
[87] {Hrelia, 2002 #97}. Likewise, while cardiomyocytes have acquired apoptosis resistance 
during differentiation [46], DOX exposure may change the balance of pro- and anti-apoptotic 
proteins in favor of the latter [25, 88] or sensitize cardiomyocytes to cell death ligands [49]. 
(Right panel) As an analogy, cancer cells are de-differentiated cells arising from differentiated 
healthy tissue [43]. On a metabolic level, this de-differentiation is characterized by increased 
glycolysis and down-regulation of mitochondrial ATP production, potentially by a shift from 
the mature to the fetal pyruvate-dependent kinase isoform [89] [90]. In addition, as cancer cells 
are continuously attacked by the immune system, the constant somatic stress makes them more 
sensitized to undergo chemotherapy-induced apoptosis. This sensitization was coined as 
apoptosis priming [45, 55] and was recently explained by us through systematic change in 
balance in favor of pro-apoptotic proteins using a systems analysis [54].  
  
Figure 3: Computational signal transduction models to translate subtle changes is 
protein and gene expression into apoptosis likelihood 
Illustration of a how a computational signal transduction analysis can quantitatively assess the 
likelihood of apoptosis downstream to MOMP in mouse hearts in the presence and absence of 
DOX pre-exposure. This analysis is based on our previously published computer model of post-
MOMP apoptosis, APOPTO-CELL. As adaptation, we also included the pro-apoptotic protein 
XAF-1 which we modelled to act in the same way as SMAC, yet to be present initially in the 
cytosol instead of being released from the mitochondria [31, 68]. As input we used gene 
expression data from Zhang [25] (GEO data set GSE36239). These authors performed an 
expression microarray analysis of heart tissue from wild type or TOP 2B -/- mice (inhibiting 
the canonical pathway of DOX) which they either subjected to PBS (control) or DOX. Hearts 
from three mice per condition were analyzed. (A) Analysis of expression profiles of apoptosis 
proteins required as input for APOPTO-CELL. Microarray read outs from GSE36239 were 
normalized to the average from the three PBS-exposed wild type mice. Results revealed that 
mice with functional TOP2B and subjected to DOX had either significantly or nearly 
significantly (n=3, *p<0.05, two sided t-test) increased XAF-1 levels compared to those mice 
where DOX was either not applied or its pathway was assumed to be non-functional (Top2b -
/-). A similar expression trend, albeit showing no significance, was observed for the pro-
apoptotic protein APAF-1. This trend was also present at much smaller extent in the pro-
apoptotic protein caspase-3. Other proteins relevant to APOPTO-CELL did not show an 
observable trend with expression differences between groups lower than a factor 1.3 and were 
hence not shown. (B) Analysis pipeline to study change in apoptosis likelihood after wild type 
and TOP2b -/- mice have been exposed to PBS or DOX. As absolute protein expressions are 
needed as model input, we assumed a set point for the relevant proteins (caspase-3: 100 nM, 
caspase-9: 10 nM, XIAP: 500 mN, APAF-1:100 nM, SMAC: 100 nM, XAF-1:100 nM). This 
set point was considered to describe the average expressions in the PBS exposed group of three 
wild type mice. From this, we used the changes in expression levels for each group (see panel 
A) and for each mouse in the group to estimate sample-individual profiles for above proteins. 
Using this as model input, APOPTO-CELL calculated the likelihood of cell death after 300 
minutes which is an estimate how PBS and DOX pre-exposed mice would react to further 
apoptosis stimuli. As result, mice with functional TOP 2B and exposed to DOX were 
statistically significantly primed to apoptosis compared to such which were either not exposed 
to DOX or where its canonical pathway was not functional (TOP2B-/-). 
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